Work

Drug-induced inflammatory colitis: a review of novel agents

Year: 2026

Type: article

Abstract: There is growing recognition of drug-induced inflammatory colitis due to increasing availability of novel therapies. This review provides an overview of contemporary drug classes causing inflammatory colitis, excluding immune checkpoint inhibitor-induced colitis which has previously been well characterised. We report on the mechanism, frequency, clinical presentation, endoscopic appearance and histopathological findings of inflammatory colitis secondary to tyrosine kinase inhibitors, phosphatidylinositol 3-kinase inhibitors, anti-IL-6 agents, IL-17 inhibitors and anti-CD20 monoclonal antibodies.

Source: npj gut and liver.

DOI: 10.1038/s44355-026-00063-1

Authors: M. Terlato, S. Dimovski, M. Burkhardt, F. Shahshahani, J. P. Segal

Institutions: The Royal Melbourne Hospital, Monash University, The University of Melbourne

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,790